Ghrelin
The body's endogenous 'hunger hormone' and natural ligand for the growth hormone secretagogue receptor, driving both GH release and appetite.
Ghrelin is an endogenous 28-amino-acid peptide hormone produced primarily by X/A-like cells of the gastric fundus and carrying a unique octanoyl (fatty-acid) modification at Ser3 that is required for binding the growth hormone secretagogue receptor (GHS-R1a). It acts as a dual regulator of GH secretion and energy homeostasis: centrally it potently stimulates pituitary GH release and promotes appetite via hypothalamic NPY/AgRP neurons, while peripherally it influences gastric motility and insulin secretion. Ghrelin itself is not administered therapeutically; its active acylated form has a very short plasma half-life and is rapidly degraded, so it is used mainly as a research tool compound, with its receptor pharmacology validated in humans through the FDA-approved agonist macimorelin.
Class
Endogenous 28-amino-acid acylated peptide hormone (growth hormone secretagogue receptor ligand)
Half-life
Very short; the active acylated form is rapidly degraded in plasma (no precise value reported in sources)
Routes
Subcutaneous, Intravenous
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Growth hormone stimulation
Ghrelin is the endogenous ligand for GHS-R1a; receptor activation in the pituitary potently and reliably stimulates GH release. This mechanism is confirmed in humans through macimorelin, where single oral doses stimulated GH secretion within 45-60 minutes with peak GH of 32-38 ng/mL.
Appetite stimulation
Acting on hypothalamic GHS-R1a receptors, ghrelin activates NPY/AgRP neurons to increase hunger and reduce energy expenditure, making it a central driver of nutritional signaling and a candidate mechanism in cachexia and appetite-loss states.
Metabolic regulation
Ghrelin integrates nutritional status with the GH axis and energy balance, with peripheral effects on gastric motility and insulin secretion. Preclinical work shows ghrelin administration can shift metabolic and proteomic pathways, including reducing markers of liver fibrosis and inflammation in a parasitic liver-injury model.
Muscle preservation / anti-cachexia potential
Because ghrelin receptor agonism raises GH and stimulates appetite and body weight, it is investigated for muscle and weight preservation. A pilot RCT of the agonist macimorelin in cancer cachexia showed numerical improvements in body weight and quality of life over one week.
Mechanism
How it works
Ghrelin must be acylated at Ser3 by the enzyme ghrelin O-acyltransferase (GOAT) to form acyl ghrelin, the active species that binds the growth hormone secretagogue receptor GHS-R1a. Without this octanoyl modification the peptide cannot engage the receptor, which is why the acyl form is the pharmacologically relevant one and why its rapid deacylation and degradation limit circulating activity.
Receptor activation in the anterior pituitary stimulates growth hormone release, positioning ghrelin as a natural counterpart to the synthetic GH secretagogues (GHRPs and ipamorelin-class peptides). In the hypothalamus, GHS-R1a signaling activates NPY/AgRP neurons, increasing appetite and reducing energy expenditure, which is the basis of ghrelin's role as the 'hunger hormone.'
Peripherally, ghrelin promotes gastric motility and modulates insulin secretion, tying gut nutrient sensing to systemic energy homeostasis. Together these central and peripheral actions make ghrelin a key integrator of nutritional status, GH axis activity, and energy balance, and explain its study across obesity, eating disorders, cachexia, and neuroendocrine physiology.
Evidence
Research & clinical studies (9)
Associations of PYY, GLP-1 and LEAP2 with changes in feeding-related cognition, body weight and glucose homeostasis after bariatric surgery in non-diabetic women
Ghrelin levels increased after bariatric surgery in non-diabetic women but without the typical post-meal variation seen in other gut hormones, and metabolic/cognitive improvements were more strongly linked to GLP-1 and PYY than to ghrelin changes.
PMID 42210737A Secondary, Subgroup Analysis of Alcohol Cue-Exposure Craving in Response to Pharmacological Inhibition of the Growth Hormone Secretagogue Receptor With PF-5190457
Examined pharmacological inhibition of the ghrelin receptor (GHS-R) with PF-5190457 on alcohol cue-exposure craving, exploring the ghrelin system as a target in alcohol use disorder.
PMID 42374967Fabrication and Characterization of Silk-Fibroin, Polyvinyl Alcohol, and Natural Compounds-Derived Bioscaffold to Accelerate Wound Healing
A bioscaffold incorporating ghrelin showed enhanced antioxidant activity and promoted endothelial cell migration and proliferation, suggesting utility for wound healing by countering oxidative stress and poor vascularization.
PMID 42216526Cortical Thickness and Appetite Hormones in Adolescent Obesity and Binge Eating Disorder: A Comparative Study
Compared cortical thickness and appetite hormones, including ghrelin, across adolescent obesity and binge eating disorder to characterize neuroendocrine correlates of disordered eating.
PMID 42365580The Carbothalamus: Villain and Victim in Metabolic Care
Reviewed hypothalamic ('carbothalamus') regulation of metabolism, situating ghrelin among the appetite and energy-balance signals central to metabolic care.
PMID 42363345Inverse Correlation Between Nesfatin-1 and Ghrelin O-Acyltransferase (GOAT) in Adolescents with Epilepsy: A Cross-Sectional Study
Adolescents with epilepsy showed markedly elevated serum nesfatin-1 and GOAT with a disease-specific inverse correlation absent in controls, suggesting dysregulation of the metabolic-excitability axis and potential biomarker value.
PMID 42194009Metabolomic and proteomic analysis of ghrelin administration in mice infected with Echinococcus granulosus
Ghrelin administration altered metabolic and protein-expression patterns—especially linoleic acid metabolism—and reduced markers of liver fibrosis and inflammation, suggesting a protective effect against parasitic liver injury.
PMID 42208921Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
Daily oral macimorelin (a ghrelin receptor agonist) was safe over one week and produced numerical improvements in body weight and quality of life in cancer cachexia (n=15), with fatigue improvement correlating with body weight, IGF-1, and caloric intake.
PMID 36860137Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study
Single-dose oral macimorelin (0.5-2.0 mg/kg) was well tolerated in healthy adults (n=28) and stimulated GH within 45-60 minutes, with peak GH of 32-38 ng/mL at the 0.5 and 1.0 mg/kg doses, confirming ghrelin receptor agonism as a GH secretory mechanism.
PMID 32325373Safety
Side effects & considerations
Contraindications & cautions
- Diabetes
- Cardiovascular condition
- Active or prior cancer history
- Pregnancy or nursing
Ghrelin carries a moderate risk profile in research contexts. Because it raises appetite, GH, and can affect insulin and cell proliferation signaling, particular caution is noted for diabetes, cardiovascular conditions, and active or prior cancer. It is research-only and not a validated human therapeutic; review all contraindications and consult a qualified professional before any use.
FAQ
Ghrelin — common questions
What is ghrelin?
Ghrelin is an endogenous 28-amino-acid peptide hormone made mainly by X/A-like cells of the gastric fundus. It carries an octanoyl modification at Ser3 that is required for binding the growth hormone secretagogue receptor (GHS-R1a), and it acts as a dual regulator of GH secretion and energy balance.
Why is ghrelin called the 'hunger hormone'?
Ghrelin activates hypothalamic GHS-R1a receptors on NPY/AgRP neurons, which increases appetite and reduces energy expenditure. It rises in relation to nutritional status and signals hunger to the brain, which is the basis of its 'hunger hormone' nickname.
What is ghrelin primarily studied for?
The main research areas are GH stimulation, appetite stimulation, metabolic regulation, and muscle preservation, spanning obesity, eating disorders, cachexia, and neuroendocrine physiology.
Is ghrelin used as a therapy or dosed like other peptides?
No. Ghrelin's active acylated form has a very short half-life and is rapidly degraded, so it is used as a research tool rather than a dosed therapeutic. Its receptor pharmacology is instead accessed clinically through macimorelin, an FDA-approved oral ghrelin receptor agonist used for diagnosing adult GH deficiency.
How does ghrelin relate to macimorelin?
Macimorelin (Macrilen) is a synthetic agonist of the same GHS-R1a receptor that ghrelin binds. It validates ghrelin receptor pharmacology in humans: trials showed it reliably stimulates GH, which led to FDA approval in 2017 for the diagnosis of adult growth hormone deficiency.
What are the safety considerations for ghrelin?
It has a moderate risk profile in research settings. Reported contraindications and considerations include diabetes, cardiovascular conditions, active or prior cancer history, and pregnancy or nursing. It is educational and research-only information—consult a qualified healthcare professional before any decision.
What does the current evidence show?
Evidence is emerging (score 0.37, based on 10 studies including 4 RCTs). Human data centers on the agonist macimorelin confirming GH stimulation, while ghrelin-focused studies explore its roles in appetite, bariatric-surgery metabolism, eating disorders, epilepsy biomarkers, and preclinical liver protection.
